No Data
No Data
Express News | Allarity Therapeutics Shares Are Trading Higher After the Company Announced That It Received Notice From the NASDAQ Stock Market That It Was Granted a Hearing
Express News | Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
Express News | Allarity Therapeutics Announces Multiple Patients In Its Phase 2 Stenoparib Trial Have Exceeded 30 Weeks On Treatment
Allarity Therapeutics' Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
Multiple patients have now exceeded 30 weeks on treatment Boston (June 25, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to
Why Allarity Therapeutics (ALLR) Stock Is Getting Hammered
Allarity Therapeutics Inc (NASDAQ:ALLR) shares are trading lower by 28.40% to $0.32 during Monday's session after the company announced it received a noncompliance letter from the Nasdaq.On June 18, A
Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining more than 300 points on Monday.The Dow traded up 0.80% to 39,463.48 while the NASDAQ fell 0.42% to 17,614.80. The S&P
No Data
RideTheTide : Good or bad news on Friday?